

Analysis of Healthcare Provider Treatment of Advanced Endometrial Cancer and Concordance With Expert Recommendations in 2023 vs 2022

Kristen M. Rosenthal, PhD,¹ Megan Cartwright, PhD,¹ Jerfiz D. Constanzo, PhD,¹ Hye Sook Chon, MD,² Linda R. Duska, MD, MPH, FACOG, FACS, FASCO,³ Ebony Hoskins, MD,⁴ Ritu Salani, MD, MBA.⁵
1. Clinical Care Options, LLC, Reston, VA. 2. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. 3. University of Virginia School of Medicine, Charlottesville, VA. 4. MedStar Washington Hospital Center, Washington, DC. 5. University of California, Los Angeles, Los Angeles, CA.
Contact: mcartwright@clinicaloptions.com

Background

- Practice patterns are rapidly evolving for treatment (tx) of advanced endometrial cancer (EC)
- Starting in 2023, NCCN guidelines^{1,2} included a recommendation of carboplatin/paclitaxel plus an immune checkpoint inhibitor (ICI) for first-line (1L) tx of advanced EC based on positive phase III data from the RUBY³ and NRG-GY018 trials⁴

Aim

- To identify **knowledge gaps** by assessing **concordance in tx selection** between healthcare professionals (HCPs) and expert recommendations on optimal tx for case scenarios provided in an online decision support tool

Methods

- An online tool was developed with 5 gynecologic oncology experts to provide **recommendations on 1L and second-line (2L) tx** of advanced EC
- HCPs entered patient case details and their planned tx** before being shown expert recommendations
- Questions were asked to assess **change in planned tx** based on expert recommendations

Conclusions

- HCPs who care for patients with advanced EC have **notable variation from 1L and 2L tx recommended by experts**
- Use of an **online decision support tool can enhance** HCP management of these patients with advanced EC to **improve patient outcomes**


1. NCCN. Clinical practice guidelines in oncology: uterine neoplasms. v.2.2023. nccn.org.
2. NCCN. Clinical practice guidelines in oncology: uterine neoplasms. v.2.2024. nccn.org.
3. Mirza. NEJM. 2023;388:2145. 4. Eskander. NEJM. 2023;388:2159.

Supported by an educational grant from GSK.

Lower Concordance Between HCPs and Experts Observed in 1L Case Scenarios With No Actionable Biomarker


Figures

Figure 1. HCP concordance with expert consensus in 1L tx selection in 2023 (n = 57 cases).



*Only 3/5 experts were in consensus for the scenario with no biomarker in each histology category.
†Clear cell, endometrioid, undifferentiated/dedifferentiated.


Impact of Tool on HCP Tx Choice and Patients in 2023



Find this poster online




Find this tool on our website



Figures


Figure 2. 131 HCPs entered 193 cases* in online tool in 2023.

- 87% of HCPs were physicians
- Most HCPs specialized in oncology/hematology (69%) or gynecologic oncology (11%)
- HCPs practiced in the United States (21%), Europe (29%), and rest of world (51%)



*n = 21 (10.9%) cases were in ≥3L setting.

Figure 3. HCP concordance with ≥1 expert in 2L tx selection in 2023.



- Consensus among ≥3/5 experts uncommon for most 2L case scenarios, except those with no biomarker
- In most 2L scenarios with no biomarker, 4-5 experts recommended lenvatinib + pembrolizumab
- For most 2L HER2-negative scenarios when prior 1L tx was plt CT + ICI, there was no expert consensus

Figure 4. Change in HCP concordance with expert consensus in 1L tx selection for HER2-negative cases From 2022 to 2023.

